Welcome to the Hope Bio Blog

By the Hope Biosciences Editorial Team HOUSTON, TX, November 20, 2019 - Hope Biosciences, a clinical stage biotechnology company focused on developing cell-based therapeutics for acute and chronic disease, today announced that FDA has authorized a Phase I/II clinical trial evaluating safety and efficacy of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) for Alzheimer’s Disease, in partnership with Altoida, Inc., a predictive digital biomarker

By the Hope Biosciences Editorial Team Update! Results of the trial announced in this press release were published in leading neurology journal Brain, Oxford Academic, and can be found here. HOUSTON, TX, October 16, 2019 – Hope Biosciences, a clinical stage biotechnology company focused on developing cell-based therapeutics for acute and chronic diseases, today announced that enrollment is now open for a Phase I/II trial evaluating safety and efficacy of Hope Biosciences’ aut